Table 2.
Demographic and clinical characteristics of patient subgroups stratified by baseline SV2A (post-hoc analysis)
|
‘No SV2A deficit’
clinical group (n=6) |
‘SV2A deficit’
clinical group (n=6) |
|||
|---|---|---|---|---|
| Age (yrs) | 34.83 (7.49) | 45.00 (12.62) | ||
| Sex (m:f) | 5:1 | 3:3 | ||
| Diagnosis | 3 MDD/PTSD, 3 PTSD | 4 MDD, 2 MDD/PTSD | ||
| No. smokers | 4 | 2 | ||
| Antidepressant use (n)a | 3 | 0 | ||
| Ketamine administered (ml) | 22.02 (3.25) | 21.42 (4.92) | ||
| Baseline | 24hr post-ketamine | Baseline | 24hr post-ketamine | |
| HAMD-17 | 14.00 (4.73) | 6.00 (3.10)* | 14.17 (4.54) | 5.83 (5.91)* |
| MADRS | 17.00 (10.04) | 6.17 (4.36)* | 19.50 (6.02) | 7.17 (6.08)* |
| BDI | 22.33 (8.07) | 13.00 (12.60)* | 21.50 (8.55) | 13.00 (12.60)* |
| PCL-5b | 43.83 (15.41) | 38.00 (11.14) | - | - |
| PCL-Sc | - | - | 30.5 (7.78) | 21.50 (6.36) |
| Injected dose (MBq) | 495.99 (183.63) | 626.97 (116.71) | 485.01 (148.79) | 440.55 (201.31) |
| Injected mass (ng/kg) | 17.34 (12.97) | 16.59 (8.95) | 10.85 (9.88) | 10.18 (11.58) |
| Free fraction (fp) | 0.27 (0.02) | 0.27 (0.02) | 0.26 (0.02) | 0.28 (0.03) |
| Parent fraction 30mins (%) | 24.43 (4.08) | 23.23 (4.22) | 27.47 (11.19) | 25.44 (7.92) |
| Parent fraction 60mins (%) | 21.65 (3.94) | 22.24 (4.71) | 22.78 (6.14) | 20.56 (5.57) |
| Clearance rate (L/h) | 84.60 (6.60) | 82.80 (17.40) | 80.40 (13.20) | 88.20 (23.40) |
HAMD-17: Hamilton depression rating scale (17-item); MADRS: Montgomery-Asberg depression rating scale; BDI: Beck depression inventory
a
n=1 subject was taking paxil, n=2 subjects were taking wellbutrin
b
n=6 individuals with PTSD were administered the PCL-5 (DSM-5 version)
c
n=2 individuals with PTSD were administered the PCL-S (DSM-IV version).